Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Dell

Internal Medicine West Bloomfield, MI Medical Doctor

NPI 1184660490 CMS profile 325411

2300 Haggerty Road, Suite 1010, West Bloomfield, MI 48323

Open in the dashboard

General payments

$7,562

459 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Dell of West Bloomfield, MI is reported in the CMS Open Payments database as having received $7,562 across 459 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $504 28
2024 General $589 34
2023 General $878 50
2022 General $988 57
2021 General $1,170 77
2020 General $1,312 95
2019 General $2,120 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Dell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lawrence Dell were reported at $504. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lawrence Dell Internal Medicine median Middle half National median
2019 $2,120 $159 $48–$570 $163
2020 $1,312 $119 $33–$402 $114
2021 $1,170 $135 $37–$521 $132
2022 $988 $141 $42–$496 $149
2023 $878 $149 $45–$519 $160
2024 $589 $154 $47–$537 $164
2025 $504 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $880 42 payments
  2. Lilly USA, LLC $783 43 payments
  3. Pfizer Inc. $758 48 payments
  4. Novo Nordisk Inc $686 51 payments
  5. GlaxoSmithKline, LLC. $624 37 payments
  6. Teva Pharmaceuticals USA, Inc. $444 29 payments
  7. Janssen Pharmaceuticals, Inc $428 34 payments
  8. Amgen Inc. $315 20 payments
  9. AbbVie, Inc. $269 16 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $267 17 payments
  11. Other $2,107 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,539 457 payments
  2. Education $22 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $533 20 payments
  2. XARELTO $412 33 payments
  3. TRELEGY ELLIPTA $402 19 payments
  4. TRULICITY $391 23 payments
  5. EUCRISA $313 19 payments
  6. Ozempic $307 26 payments
  7. MOUNJARO $295 13 payments
  8. RYBELSUS $280 24 payments
  9. JARDIANCE $269 21 payments
  10. PREVNAR 20 $233 14 payments
  11. Other $6,571 435 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

4,318

Median for Internal Medicine: 777

Drug cost

$454,155

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 125 $125,218
Ozempic Semaglutide Brand 37 $71,446
Mounjaro Tirzepatide Brand 53 $59,584
Xarelto Rivaroxaban Brand 60 $43,904
Eliquis Apixaban Brand 51 $42,646
Entresto Sacubitril/Valsartan Brand 21 $23,797
Januvia Sitagliptin Phosphate Brand 21 $15,243
Myrbetriq Mirabegron Brand 12 $8,941
Atorvastatin Calcium Generic 367 $5,248
Levothyroxine Sodium Generic 226 $2,674

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 200 billing codes

Paid by Medicare

$433,620

Of which drugs: $27,865

Medicare patients

1,777

Average age 74

Services billed

14,430

1,075 women, 702 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Ischemic heart disease 30%
Diabetes 29%
Chronic kidney disease 21%
Depression 18%
Atrial fibrillation 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 83 84 $12,615
Vaccine for influenza for injection into muscle 90662 Office 123 126 $10,185
Pcv20 vaccine im 90677 Office 13 13 $3,400
Injection, methylprednisolone acetate, 1 mg J1010 Office 51 5,120 $508
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 16 16 $419
Injection, ketorolac tromethamine, per 15 mg J1885 Office 96 309 $154
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 32 716 $150
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 44 71 $65
Injection, ceftriaxone sodium, per 250 mg J0696 Office 28 104 $35
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 123 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $71
$71 125 —
Wegovy
  • Novo Nordisk Inc $47
$47 — —
MOUNJARO
  • Lilly USA, LLC $45
$45 53 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $36
$36 — —
RYBELSUS
  • Novo Nordisk Inc $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

459 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record